The tender titled Antispasmodic Tab containing Mefenamic Acid 250 mg & Dicyclomine HCl 10 mg with reference number GEM/2025/B/6030239 is issued by the Department of Defence under the Ministry of Defence. This tender invites suppliers to submit bids for the procurement of a significant quantity of antispasmodic tablets intended for various medical applications.

Scope of Work and Objectives

The primary objective of this tender is to source antispasmodic tablets containing Mefenamic Acid and Dicyclomine HCl, specifically in the stated dosages of 250 mg and 10 mg respectively. The total quantity required for this tender is 402,700 tablets, which are essential in providing therapeutic treatments for conditions that cause spasms, particularly in the gastrointestinal tract.

Eligibility Criteria

To be eligible to participate in this tender, bidders must meet specific requirements. These include being a registered entity capable of handling large-scale pharmaceutical supply and adhering to applicable regulatory standards. Eligible participants must demonstrate prior experience in supplying pharmaceutical products to government or private sectors. Additionally, bidders must provide evidence of compliance with quality and safety standards pertinent to drug manufacturing and distribution.

Technical Requirements

Technical requirements for this tender include the provision of detailed specifications of the antispasmodic tablets, ensuring that they meet strict quality standards. Suppliers must produce pharmacological documentation that outlines the safety and efficacy of the medication as well as adherence to rigorous quality control protocols.

Financial Requirements

Bidders are expected to present comprehensive financial bids that reflect competitive pricing while ensuring that the antispasmodic tablets meet the specified quality standards. The financial documentation must include a clear breakdown of costs associated with production, packaging, and delivery.

Document Submission Details

All documents must be submitted electronically. Bidders should include their complete proposals, including technical specifications, financial bids, and any relevant certifications, through the designated submission platform. Late submissions or incomplete bids will be disqualified.

Special Provisions

This tender encourages participation from Micro, Small, and Medium Enterprises (MSEs), providing benefits such as preferential consideration within the evaluation process and potential financial support mechanisms. Startups also receive special provisions to enhance competitiveness and participation in the tender.

Evaluation Process

The evaluation process will involve a thorough review of technical and financial proposals. Factors such as compliance with specifications, quality assurance processes, and overall pricing will be critical in selecting the best bid. The assessment is designed to identify suppliers that not only offer competitive prices but also demonstrate a commitment to high-quality standards within the pharmaceutical industry.

Delivery Locations

The delivery of the antispasmodic tablets will be expected at various designated locations outlined in the tender criteria. It is crucial that bidders are capable of meeting logistical requirements to ensure timely deliveries.

Contact Information

For further queries related to the tender specifications, eligibility, and submission processes, bidders can reach out to the Department of Defence through official communication channels provided in the tender documentation.

Conclusion

This tender for Antispasmodic Tab containing Mefenamic Acid 250 mg & Dicyclomine HCl 10 mg presents a robust opportunity for pharmaceutical suppliers looking to collaborate with the Department of Defence. Bidders are encouraged to submit thorough and compliant proposals that respect the outlined criteria, ensuring not only their qualification for consideration but also their commitment to the efficacy and safety of the medicinals being offered.